Literature DB >> 16511924

Proton magnetic resonance spectroscopy reveals central neuroaxonal impairment in systemic sclerosis.

Luca Bertinotti1, Marzia Mortilla, Maria Letizia Conforti, Nicola Colangelo, Francesca Nacci, Angela Del Rosso, Claudio Fonda, Roberto Casale, Marco Matucci-Cerinic, Alberto Pignone.   

Abstract

OBJECTIVE: . Involvement of the central nervous system (CNS) in systemic sclerosis (SSc) is rare. Proton magnetic resonance spectroscopy (1H-MRS) assesses in vivo cerebral metabolites. We investigated the biochemical modifications of the CNS in SSc.
METHODS: N-acetylaspartate/creatine ratio (NAA/Cr) and choline/creatine ratio (Cho/Cr) at right centrum semiovale (RCS) and at right basal ganglia (RBG) were evaluated by 1H-MRS in 12 patients with limited (lSSc) and 8 patients with diffuse SSc (dSSc) and 20 control subjects.
RESULTS: With 1H-MRS, a significant reduction of NAA/Cr ratio at RBG (p < 0.02) and at RCS (p < 0.002) was detected in SSc patients. Cho/Cr ratio was increased (p < 0.02) in the RCS, but not in RBG. In patients with lSSc, a significant reduction of NAA/Cr was detected in RCS but not in RBG.
CONCLUSION: Evidence of neuroaxonal damage strongly suggests the existence of CNS involvement in SSc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511924

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  Neurosonological and cognitive screening for evaluation of systemic sclerosis patients.

Authors:  B R Sakr; R E Rabea; A M Aboulfotooh; N A Kishk
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

Review 2.  Cardiovascular disease in systemic sclerosis.

Authors:  Francesca Cannarile; Valentina Valentini; Giulia Mirabelli; Alessia Alunno; Riccardo Terenzi; Filippo Luccioli; Roberto Gerli; Elena Bartoloni
Journal:  Ann Transl Med       Date:  2015-01

Review 3.  Acute cerebral vasculopathy in systemic sclerosis.

Authors:  Benoit Faucher; Brigitte Granel; Francois Nicoli
Journal:  Rheumatol Int       Date:  2012-12-23       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.